VC firms
Ventura BioMed invests in early-stage life science companies developing pioneering technologies and innovative therapies.
Overview
Investment Stage
Pre-Seed; Seed; Series A
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 6, 2025 | CHF 6.3 million to advance next-generation biomarker technology | arcoris bio develops next-generation technologies for biomarker detection in research and diagnostics. MUSE, arcoris bio’s nanotechnology platform for biomarker detection and signal amplification, enables simultaneous detection of multiple... |
| Nov 11, 2022 | Navignostics raises CHF 7.5M to advance precision cancer medicine | |
| Oct 10, 2022 | IRUBIS completes €2.8 million seed funding for real-time measurement of bioprocesses | Biotech startup Irubis has closed a €2.8 million seed funding round. The company aims to automate process development and manufacturing of biopharmaceutical drugs and has developed a technology that is a plug-and-play system that simplifies... |
| Oct 6, 2022 | Real-Time Monitoring of Bioprocesses: IRUBIS closes EUR 2.8m seed round led by HTGF, Verve Ventures and Ventura BioMed Investors | October 6, 2022 |
| Oct 1, 2022 | Kupando raises €13 million in Series A funding round | |
| Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million | October 14, 2021 |
Reviews 0
FAQ about Ventura BioMed
What has the press written about Ventura BioMed?
Parsers VC has collected 7 articles mentioning Ventura BioMed, among them “CHF 6.3 million to advance next-generation biomarker technology” (Nov 6, 2025) and “Navignostics raises CHF 7.5M to advance precision cancer medicine” (Nov 11, 2022).
Is Ventura BioMed still active?
Ventura BioMed is probably closed: its latest activity on Parsers VC dates from Nov 8, 2025.